IMP321: Phase I/IIa data

An open-label, Swiss Phase I/IIa trial in 16 patients with metastatic melanoma showed that 5 synthetic melanoma peptides antigens plus IMP321 and montanide adjuvant led to antigen-specific CD8 T cell...